Skip to main content
Premium Trial:

Request an Annual Quote

Rockland Immunochemicals Buys Line of Antibodies for Epigenetics Research

NEW YORK (GenomeWeb News) – Research reagents company Rockland Immunochemicals today said it has purchased the Epi-Plus antibody product line from 21st Century Biochemicals for an undisclosed amount.

Epi-Plus antibodies are used for epigenetics research and have been validated by multi-assay methods, including dot blot testing using modified peptide arrays, Western blots, and chromatin immunoprecipitation.

Rockland said that studies have indicated that epigenetic pharmaceuticals may be a putative replacement or adjuvant therapy for current methods such as radiation and chemotherapy and noted that the global market for epigenetics is estimated to reach $8 billion by 2017, compared to $2.6 billion in 2012.

Jim Fendrick, president and CEO of Rockland, said in a statement that the deal expands the firm's life science tools portfolio "and will allow our customers to perform their research in a more efficient and effective manner, ultimately saving time and precious research dollars." He also said that the Epi-Plus brand is co-owned by Novus Biologicals, which will allow Rockland to expand its brand worldwide.

In December Gilbertsville, Penn.-based Rockland purchased the Trueblot IP/Western blot product line from Affymetrix's eBioscience business.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.